Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.70 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.70 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.70 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.56 |
| ▸ | MGAM | O43451 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | SI | P14410 | 3/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945642 | 0.86 | SLC9A1 (0.57) | NR4A1NR4A2NR4A3SLC9A1PDE4B | |
| SCHEMBL13078324 | 0.84 | NR4A1 (0.74) | NR4A1NR4A2NR4A3SLC9A1PDE4B | |
| SCHEMBL4943045 | 0.83 | SLC9A1 (0.62) | NR4A1NR4A2NR4A3SLC9A1CYP1A2 | |
| SCHEMBL1317340 | 0.83 | HSD17B1 (0.55) | NR4A1NR4A2NR4A3SLC9A1PDE4B | |
| SCHEMBL3050183 | 0.83 | NR4A1 (1.00) | NR4A1NR4A2NR4A3SLC9A1PDE4B | |
| SCHEMBL4939182 | 0.82 | SLC9A1 (0.65) | SLC9A1CYP1A2CYP2C19ALDH1A1HPGD | |
| SCHEMBL4945600 | 0.82 | ALDH1A1 (0.67) | SLC9A1PDE4BMGAMGAASI | |
| SCHEMBL1143419 | 0.82 | ALDH1A1 (0.53) | NR4A1NR4A2NR4A3SLC9A1GAA | |
| SCHEMBL6671019 | 0.81 | NR4A1 (0.74) | NR4A1NR4A2NR4A3SLC9A1PDE4B | |
| SCHEMBL29353751 | 0.81 | NR4A1 (0.74) | NR4A1NR4A2NR4A3SLC9A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351843-B2 | Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-04-01 | — | — | US | disclosed |
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-12-27 | — | — | US | disclosed |
| EP-1697335-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063727-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299131-A1 | Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them | SLC9A1, NHERF1, SLC5A1 | NR4A1 4396/4885NR4A2 4318/4885NR4A3 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.